A Window-of-opportunity Study of U3-1402, a HER3-targeting Antibody-drug Conjugate in Operable Breast Cancer According to ERBB3 Expression
Latest Information Update: 21 Feb 2024
At a glance
- Drugs Patritumab Deruxtecan (Primary)
- Indications Adenocarcinoma; Early breast cancer; HER2 negative breast cancer; Male breast cancer; Triple negative breast cancer
- Focus Therapeutic Use
- Acronyms TOT-HER3
- 21 Jun 2023 Planned End Date changed from 30 Apr 2023 to 30 Sep 2023.
- 19 May 2023 Primary endpoint (CelTIL score) has been met according to results published in the Annals of Oncology.
- 19 May 2023 Status changed from recruiting to completed according to results published in the Annals of Oncology.